⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PYXS News
Pyxis Oncology, Inc. Common Stock
Form 8-K
sec.gov
PYXS
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
globenewswire.com
PYXS
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
globenewswire.com
PYXS
Form 8-K
sec.gov
PYXS
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
globenewswire.com
PYXS
Pyxis Oncology to Participate in Upcoming Investor Conferences
globenewswire.com
PYXS
Form 8-K
sec.gov
PYXS
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
globenewswire.com
PYXS
Form 8-K
sec.gov
PYXS
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
globenewswire.com
PYXS